{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:00:32Z","timestamp":1780992032195,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.12.012","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:15:22Z","timestamp":1766164522000},"page":"142-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma: A Comprehensive Review"],"prefix":"10.1016","volume":"26","author":[{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-0049","authenticated-orcid":false,"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.12.012_bib0001","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0002","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.012_bib0003","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.2019896688","article-title":"Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL","volume":"133","author":"Ahn","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0004","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haemotologia"},{"key":"10.1016\/j.clml.2025.12.012_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0007","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.012_bib0008","series-title":"Prescribing information","year":"2024"},{"key":"10.1016\/j.clml.2025.12.012_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/cancers15020507","article-title":"Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for \u22655 years in the RESONATE-2 study","volume":"15","author":"Woyach","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.12.012_bib0010","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.12.012_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.12.012_bib0012","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.12.012_bib0013","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.012_bib0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40801-022-00332-4","article-title":"Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"10","author":"Lee","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.clml.2025.12.012_bib0015","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clml.2025.12.012_bib0016","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/03007995.2024.2368175","article-title":"Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy\/chemoimmunotherapy","volume":"40","author":"Robak","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2025.12.012_bib0017","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/bloodadvances.2024015417","article-title":"Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL\/SLL","volume":"9","author":"Allan","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.012_bib0018","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1002\/hem3.74","article-title":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: a pooled post hoc analysis","volume":"8","author":"Ghia","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.12.012_bib0019","series-title":"First line (1L) ibrutinib (IBR) in patients (PTS) with chronic lymphocytic leukemia (CLL) demonstrates overall survival (OS) comparable to an age-matched European population","author":"Ghia","year":"2024"},{"key":"10.1016\/j.clml.2025.12.012_bib0020","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0021","article-title":"Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon-2023-0436","article-title":"Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib","volume":"20","author":"Jacobs","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19056","volume":"40","author":"Vose","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0024","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S2152-2650(22)01341-6","article-title":"CLL-345 retrospective analysis of real-world outcomes of chronic\/small lymphocytic leukemia (CLL\/SLL) patients treated with first-line ibrutinib versus chemoimmunotherapy (CIT)","volume":"22","author":"Ran","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.012_bib0025","first-page":"1266","article-title":"Time to next treatment, health care resource utilization, and costs associated with ibrutinib use among U.S. Veterans with chronic lymphocytic leukemia\/small lymphocytic lymphoma: a real-world retrospective analysis","volume":"26","author":"Huang","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2025.12.012_bib0026","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0027","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/PPA.S417180","article-title":"Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia","volume":"17","author":"Lu","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2025.12.012_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/JBM.S202286","article-title":"Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis","volume":"10","author":"Nuttall","year":"2019","journal-title":"J Blood Med"},{"key":"10.1016\/j.clml.2025.12.012_bib0029","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0030","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/S2152-2650(23)01116-3","article-title":"Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database","volume":"23","author":"Ghosh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.012_bib0031","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2023-181774","article-title":"Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0032","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1200\/JCO.2023.41.16_suppl.7537","article-title":"Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)","volume":"41","author":"Rogers","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0033","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/S2152-2650(23)01111-4","article-title":"Real-world dosing patterns and time to next treatment for previously untreated patients with CLL\/SLL with or without ibrutinib dose reduction following an adverse event","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.012_bib0034","doi-asserted-by":"crossref","first-page":"e19017","DOI":"10.1200\/JCO.2024.42.16_suppl.e19017","article-title":"Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"42","author":"Shadman","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0035","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2025.12.012_bib0036","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/10428194.2024.2402814","article-title":"Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"66","author":"Shadman","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.12.012_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100022","article-title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation","volume":"1","author":"Ghosh","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2025.12.012_bib0038","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/S2152-2650(24)01277-1","article-title":"CLL-402 real-world clinical outcomes of first-line (1L) Ibrutinib dose reduction versus acalabrutinib among patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"24","author":"Shadman","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.012_bib0039","first-page":"4313","article-title":"The Impact of front-line ibrutinib dose reduction and interruption on outcomes in chronic lymphocytic leukemia (CLL) patients","volume":"130","author":"Rhodes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0040","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.jval.2023.09.959","article-title":"Evaluation of healthcare resource utilization and cost among first-line patients receiving ibrutinib vs acalabrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a commercial claims database analysis","volume":"26","author":"Muluneh","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2025.12.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2025.04.2020","article-title":"Healthcare cost comparison between 1L ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the veterans affairs population","volume":"28","author":"Fitzgerald","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2025.12.012_bib0042","doi-asserted-by":"crossref","first-page":"HSR25","DOI":"10.6004\/jnccn.2024.7351","article-title":"Cost-effectiveness evaluation of bruton tyrosine kinase inhibitor (BTKi) treatments among medicare patients with chronic lymphocytic leukemia (CLL) in first-line (1L) and relapsed\/refractory (R\/R) settings","volume":"23","author":"Crawford","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.12.012_bib0043","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1182\/bloodadvances.2022008068","article-title":"Real-world prognostic testing and treatment patterns in CLL\/SLL: results from 1462 patients in the informCLL registry","volume":"7","author":"Mato","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.012_bib0044","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.12.012_bib0046","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0047","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0048","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.012_bib0049","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e19020","article-title":"Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in US community oncology practices","volume":"42","author":"Hou","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0051","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e19022","article-title":"Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL\/SLL","volume":"42","author":"Pinilla-Ibarz","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.012_bib0052","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","article-title":"Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials","volume":"41","author":"Stephens","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:45:08Z","timestamp":1780991108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025043071"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma: A Comprehensive Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}